New obesity drug shows promise for teens in early trial
NCT ID NCT07693426
First seen Jul 09, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This study tests a new drug called efsubaglutide alfa in Chinese adolescents aged 12 to 17 with obesity. The goal is to check the drug's safety, how the body processes it, and its effects on weight. Participants receive either the drug or a placebo injection weekly for 12 weeks. The trial is small and early-stage, so it focuses on safety and dosing rather than proving the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- efsubaglutide alfa
- What this could lead to
- If safe and effective, this drug could offer a new treatment option for obesity in adolescents, helping reduce weight and improve health.
- What could go wrong
- This is an early phase 1 trial with only 36 participants, so results may not apply broadly. Side effects or lack of efficacy are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADOLESCENCE OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Chaoyang Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
-
Qilu Hospital, Shandong University
NOT_YET_RECRUITINGJinan, Shandong, China
-
Qilu Second Hospital, Shandong University
RECRUITINGJinan, Shandong, China
-
Shengjing Hospital, China Medical University
NOT_YET_RECRUITINGShenyang, Liaoning, China
-
Wuhan Central Hospital
NOT_YET_RECRUITINGWuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.